Alcohol Addiction Treatment in Southern California

By SoCal Addiction Centers Editorial Team | Last reviewed: | 19 min read Clinically Reviewed

Key Takeaways

  • Alcohol-use disorder (AUD) is the single most common SUD admission type in California, across every insurance category and county. It is also the withdrawal category where unmanaged detox carries the highest mortality risk — severe alcohol withdrawal can cause seizures, delirium tremens (DTs), and death.
  • Withdrawal management is CIWA-Ar driven. The Clinical Institute Withdrawal Assessment for Alcohol (revised) is the standard scoring tool used to guide medication dosing. Mild withdrawal (CIWA <10) can be managed outpatient; moderate (10–20) typically requires residential or 3.2-WM; severe (>20) or with complications requires 3.7-WM or hospital-level 4.0-WM detox.
  • Three FDA-approved maintenance medications: naltrexone (oral or Vivitrol monthly injection), acamprosate (Campral), and disulfiram (Antabuse). Each has a different mechanism and patient fit. All three are covered under Medi-Cal DMC-ODS, Medicare Part B, and commercial insurance under parity.
  • SoCal flagship facilities for AUD residential include Phoenix House Orange County (Santa Ana, 128-bed), MLK Jr. Behavioral Health Center (Los Angeles, 99-bed), Socorro (Los Angeles, 75-bed), Allen House (Santa Fe Springs, 60-bed), Prototypes Women’s Center (Pomona, 164-bed women-specific).
  • CDPH data: California recorded approximately 10,000+ alcohol-related deaths annually in recent years, including liver disease, alcohol-related injuries, and acute alcohol poisoning, per published state mortality data. Alcohol-related hospital admissions in California run several multiples of overdose deaths.
  • Two clinical truths most marketing content obscures: (1) medication-assisted treatment for alcohol is substantially underutilized relative to its evidence base, and (2) the 28-day residential model that dominates AUD treatment is based on historical convention more than clinical evidence — ASAM guidelines support longer stays for moderate-to-severe cases.

Alcohol addiction treatment in Southern California — a clinical overview

Alcohol-use disorder treatment in Southern California follows the ASAM Criteria clinical framework, with withdrawal management via CIWA-Ar-scored benzodiazepine protocols and maintenance supported by three FDA-approved medications (naltrexone, acamprosate, disulfiram). This page is a clinical-specificity counterpart to marketing-driven content about “alcohol rehab in California” — which dominates the SERP but rarely names the ASAM levels of care, the withdrawal scoring tools, or the medication protocols clinicians actually use. We name them here, and we cross-reference every facility mentioned against the DHCS Licensing and Certification Division public dataset and CARF provider search.

No referral fees. No paid listings. This guide is written for patients and families making treatment decisions and for clinicians looking for a clean SoCal clinical reference.

Why alcohol withdrawal is medically different

Alcohol, benzodiazepines, and barbiturates are the three substance categories where unmanaged withdrawal can be fatal. Opioid withdrawal is severe and miserable but is rarely fatal in an otherwise healthy patient. Alcohol withdrawal kills through three mechanisms:

  • Withdrawal seizures — typically 12–48 hours after last drink in chronic heavy drinkers. Can be unpredictable; can present without warning.
  • Delirium tremens (DTs) — onset 48–96 hours after cessation, characterized by autonomic instability, hallucinations, disorientation. Untreated DTs mortality historically ran 15–20%; with modern medical management, mortality is <5% but still substantial.
  • Cardiovascular complications — autonomic hyperactivity during withdrawal can destabilize pre-existing cardiac disease.

Risk factors for severe withdrawal include prior history of withdrawal seizures or DTs, daily drinking >10 drinks for months, medical comorbidities (liver disease, cardiovascular disease, older age), concurrent benzodiazepine use, and malnutrition.

The CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol, revised) is the standard scoring tool used in SoCal detox and residential programs. It assesses 10 withdrawal symptoms (nausea, tremor, paroxysmal sweats, anxiety, agitation, tactile/auditory/visual disturbances, headache, orientation) on 0–7 scales and produces a composite score. CIWA-Ar is administered at intake and at 1–4 hour intervals during active withdrawal, with medication (typically a long-acting benzodiazepine) dosed to the score.

Medications used in alcohol withdrawal

Long-acting benzodiazepines — first-line for CIWA-Ar-driven withdrawal management. Choices include:

  • Chlordiazepoxide (Librium) — long-acting, smooth taper. First-line in most SoCal detox protocols.
  • Diazepam (Valium) — long-acting, rapid onset. Common alternative.
  • Lorazepam (Ativan) — shorter-acting, no active metabolites. Preferred in patients with hepatic impairment (lorazepam is not liver-metabolized the way diazepam is).
  • Oxazepam (Serax) — also preferred in hepatic impairment.

Dosing is symptom-triggered (dose when CIWA-Ar score rises) rather than fixed-schedule in most modern protocols. Symptom-triggered dosing typically uses less total benzodiazepine and shortens detox duration.

Phenobarbital — used in severe withdrawal or benzodiazepine-refractory cases. Some programs now use phenobarbital as primary rather than adjunct.

Anticonvulsants (carbamazepine, gabapentin) — adjuncts for mild-to-moderate withdrawal or for patients where benzodiazepines are contraindicated.

Thiamine and folic acid — standard supportive care. Alcohol-dependent patients are often thiamine-deficient, and thiamine prophylaxis prevents Wernicke encephalopathy (a preventable, devastating thiamine-deficiency syndrome). Thiamine should be administered before any glucose-containing IV fluids in withdrawal patients.

Multivitamins, magnesium repletion — standard supportive measures.

Withdrawal severity stratification

Matching the level of care to withdrawal severity is a clinical judgment, not a standardized protocol-driven decision. Providers rely on several frameworks in combination.

CIWA-Ar score interpretation

  • Score 0–9: mild withdrawal. Ambulatory withdrawal management (ASAM 1-WM or 2-WM) often clinically appropriate for patients with stable social support and no medical complications.
  • Score 10–19: moderate withdrawal. Residential withdrawal management (3.2-WM) or medically monitored inpatient (3.7-WM) typically indicated.
  • Score 20+: severe withdrawal. Medically monitored (3.7-WM) or medically managed (4.0-WM) inpatient indicated. High risk of complications.
  • Scores plus red-flag features (seizure history, DT history, unstable vital signs): inpatient / hospital-level care regardless of CIWA-Ar absolute number.

DSM-5-TR alcohol withdrawal criteria

The DSM-5-TR recognizes alcohol withdrawal with three modifiers relevant to treatment planning:

  • With perceptual disturbances — tactile, visual, or auditory hallucinations. Indicates more severe withdrawal; elevated inpatient-level-of-care indication.
  • Uncomplicated vs complicated — complicated withdrawal includes withdrawal seizures, delirium tremens, or significant autonomic instability.

Complicated withdrawal — the high-risk subset

Alcohol withdrawal seizures:

  • Typically occur 6–48 hours after last drink in chronic heavy drinkers
  • Generalized tonic-clonic seizures; typically single rather than multiple
  • Status epilepticus is rare but possible
  • Prior withdrawal seizure is the strongest predictor of recurrent seizures during subsequent withdrawal episodes

Delirium tremens (DTs):

  • Onset 48–96 hours (sometimes up to 7 days) after cessation
  • Hallmarks: severe autonomic instability (tachycardia, hypertension, fever), profound confusion, vivid hallucinations (classically tactile — “formication”), tremulousness
  • Historically fatal in 15–20% of untreated cases; modern medical management reduces mortality substantially but not to zero
  • Requires hospital-level care (ASAM 4.0-WM)

Medical vs social detox

Medical detox — ASAM 3.2-WM, 3.7-WM, or 4.0-WM — provides medication-supported, medically-supervised withdrawal management. Appropriate for all patients with moderate-to-severe withdrawal risk.

“Social detox” — a historically common California program model that provides supportive housing and peer support during withdrawal but without active medical management. May be appropriate for patients with mild withdrawal only, low medical risk, and no history of complicated withdrawal. Social detox programs are declining in prevalence as clinical standards have evolved; California’s DHCS DMC-ODS framework emphasizes medical detox appropriate to clinical need.

Clinical rule of thumb: if there’s genuine uncertainty about whether a patient needs medical detox versus social detox, err toward medical detox. Unmanaged alcohol withdrawal can be fatal in ways few other substance categories produce.

Liver disease and AUD treatment — critical considerations

Alcoholic liver disease is common in chronic heavy drinkers and substantially affects AUD medication choices and withdrawal management.

Alcoholic hepatitis and decompensated cirrhosis

Alcoholic hepatitis (acute inflammatory liver disease from alcohol) — more severe forms (Maddrey Discriminant Function >32, MELD score elevated) carry 30-day mortality in the double digits. Acute alcoholic hepatitis requires hospital-level management, often ICU-level for severe cases. SUD treatment in the acute hepatitis window is integrated with medical stabilization.

Decompensated cirrhosis — hepatic encephalopathy, ascites, variceal bleeding, or hepatorenal syndrome. Medication selection and dosing must account for hepatic clearance impairment.

Medication interactions with liver disease

Naltrexone:

  • Contraindicated in acute hepatitis and severe hepatic impairment
  • Oral naltrexone carries FDA boxed warning for hepatotoxicity at high doses
  • Vivitrol (extended-release injection) similar cautions
  • Generally avoided until liver function stabilizes

Acamprosate:

  • Renally cleared, not liver-metabolized
  • Usable in patients with significant liver disease (often preferred when hepatic function is a concern)
  • Dose reduction required for severe renal impairment

Disulfiram:

  • FDA boxed warning for hepatotoxicity; disulfiram itself can cause liver injury
  • Contraindicated in patients with significant liver disease
  • Alcohol-disulfiram reaction would be particularly dangerous in liver-compromised patients

Benzodiazepines during withdrawal with hepatic impairment:

  • Lorazepam (Ativan) and oxazepam (Serax) are preferred — both are metabolized by glucuronidation (not CYP oxidation) and do not produce active metabolites; accumulate less in hepatic impairment
  • Chlordiazepoxide and diazepam have active metabolites that can accumulate in liver disease, producing excessive sedation

Liver disease management as part of AUD treatment

Patients with AUD and liver disease benefit from integrated hepatology + addiction medicine management. Continued alcohol use with decompensated cirrhosis is frequently fatal; achieving and maintaining abstinence is clinically essential. Residential SUD programs at CARF-accredited facilities with hepatology referral capacity, or embedded medical hospital-based SUD programs, are appropriate settings for patients with significant liver disease.

Off-label AUD medications — established evidence base

Beyond the three FDA-approved medications (naltrexone, acamprosate, disulfiram), several additional medications have established evidence bases for AUD treatment but are prescribed off-label for this indication.

Topiramate:

  • FDA-approved for epilepsy and migraine prophylaxis
  • Established evidence base in AUD trials (Kranzler and colleagues, among others) for reducing heavy drinking days and supporting abstinence
  • Dosed gradually (titrated up to 150–300 mg/day typically)
  • Side effects include cognitive slowing (“word-finding difficulty”), paresthesias, kidney-stone risk
  • Used widely for AUD in practice despite off-label status

Gabapentin:

  • FDA-approved for neuropathic pain, partial-onset seizures, post-herpetic neuralgia
  • Established evidence base for AUD including reduced heavy drinking and improved sleep during early abstinence
  • Dosed 600–1,800 mg/day for AUD typically
  • Better tolerated than topiramate for many patients
  • Caveat: has some potential for misuse, particularly in polysubstance use contexts

Baclofen:

  • FDA-approved for spasticity
  • Evidence base is mixed; used more in Europe than US for AUD
  • Some evidence for high-dose baclofen in patients with comorbid liver disease where naltrexone is contraindicated
  • Side effects include sedation, withdrawal symptoms with abrupt discontinuation

Ondansetron (5-HT3 antagonist):

  • FDA-approved as antiemetic
  • Evidence for specific AUD phenotypes (early-onset alcoholism, genetically-defined subgroups)
  • Not mainstream AUD treatment; relevant in specific clinical subsets

These off-label options are particularly relevant for patients who have not responded to FDA-approved medications, have contraindications to them, or have specific comorbidities (e.g., baclofen for patients with liver disease).

FDA-approved medications for alcohol-use disorder maintenance

Three medications are FDA-approved for AUD. They address the underlying disorder after withdrawal is resolved, supporting sobriety and reducing relapse risk. All three are substantially underutilized relative to their evidence base; many patients with AUD are never offered medication.

Naltrexone (oral and extended-release injection)

Mechanism: mu-opioid receptor antagonist. Blocks the rewarding effects of alcohol (which are partially mediated through endogenous opioid release).

Formulations:

  • Oral tablet — 50 mg daily. Adherence is the main limitation.
  • Vivitrol — 380 mg monthly intramuscular injection. Removes daily adherence burden.

Clinical evidence: reduces heavy drinking days and supports abstinence. Effect size is modest but clinically meaningful; works best in patients with family history of alcoholism and strong craving components.

Contraindications: current opioid use (precipitates opioid withdrawal), severe liver disease.

Acamprosate (Campral)

Mechanism: modulates glutamate/GABA systems in the post-acute withdrawal phase. Reduces protracted withdrawal symptoms (anxiety, insomnia, dysphoria) that drive relapse.

Dosing: 666 mg three times daily (oral). Typical initiation after 5 days of abstinence and completed acute withdrawal.

Clinical evidence: reduces relapse rate, particularly in patients with protracted post-acute withdrawal symptoms. Works best in patients who have completed detox and are abstinent at initiation.

Contraindications: severe renal impairment (acamprosate is renally cleared).

Disulfiram (Antabuse)

Mechanism: aldehyde dehydrogenase inhibitor. Drinking alcohol on disulfiram produces severe aversive reaction (flushing, nausea, tachycardia, hypotension).

Dosing: 250 mg daily (oral). Observed dosing (in residential or with family involvement) improves adherence.

Clinical evidence: effective when taken consistently; limited by adherence. Best suited to highly motivated patients with strong support systems or observed-dosing arrangements.

Contraindications: cardiovascular disease, hepatic disease, psychosis; patient must be fully abstinent and informed about the aversive reaction.

Other medications with evidence for AUD (not FDA-approved for this indication but used off-label):

  • Topiramate — reduces craving and heavy drinking
  • Gabapentin — useful in patients with anxiety/sleep comorbidities
  • Baclofen — some evidence, variable trial results

ASAM levels of care for AUD

Alcohol-use disorder can be treated at any ASAM level, with placement depending on withdrawal severity, medical complexity, psychiatric comorbidity, and social environment:

Level 1.0 — Outpatient. Appropriate for mild AUD, stable social support, no active withdrawal. Outpatient counseling (individual or group), primary care MAT prescribing, community support (AA, SMART Recovery, Refuge Recovery).

Level 2.1 — Intensive Outpatient (IOP). 9+ hours/week. Appropriate for moderate AUD or as step-down from residential. MAT continuation in outpatient setting.

Level 2.5 — Partial Hospitalization (PHP). 20+ hours/week. Appropriate when IOP isn’t intensive enough but residential isn’t needed.

Level 3.1, 3.3, 3.5 — Clinically Managed Residential. 24-hour care. Appropriate for moderate-to-severe AUD with unstable home environment or prior treatment failures. Typical 28–90 day stays.

Level 3.7 — Medically Monitored Inpatient. 24-hour medical and nursing care. Appropriate for severe AUD, high CIWA-Ar scores, significant medical comorbidity, complex polysubstance picture, or failed outpatient detox.

Level 3.2-WM and 3.7-WM — Withdrawal Management. Detox-specific levels. 3.2-WM is clinically managed residential detox; 3.7-WM is medically monitored inpatient detox. Typical length 5–7 days for alcohol.

Level 4.0-WM — Medically Managed Inpatient. Hospital-level detox. Appropriate for prior DT history, severe medical complications, or patients who require 24-hour physician coverage (not just on-call).

For comprehensive level-of-care detail, see our medical detox pillar and inpatient/residential pillar.

SoCal flagship facilities for alcohol-use disorder treatment

Our flagship tier requires current DHCS license, SAMHSA National Directory match, CARF accreditation for SUD-specific programs, and multiple levels of care. Flagship facilities commonly treating AUD across SoCal:

Large-capacity residential (AUD patients):

  • Prototypes Women’s Center (Pomona, LA County) — 164-bed women-specific, CARF Residential Treatment (BH). Nationally-known women’s residential program with significant AUD treatment population.
  • Phoenix House Orange County, Inc. (Santa Ana, OC) — 128-bed, CARF Detox/WM Residential. Large-scale county-funded capacity; broad insurance acceptance.
  • MLK Jr. Behavioral Health Center (Los Angeles, LA County) — 99-bed, CARF Residential Treatment (BH). South LA anchor, county-funded.
  • Socorro (Los Angeles, LA County) — 75-bed, CARF Detox/WM Residential + Residential Treatment.
  • Allen House (Santa Fe Springs, LA County) — 60-bed, CARF IOP + Outpatient (BH).

Specialty capacity:

  • The Ranch (Desert Hot Springs, Riverside County) — 46-bed, CARF Detox/WM Residential. Coachella Valley anchor.
  • Hacienda Valdez (Desert Hot Springs, Riverside County) — 35-bed verified tier, CARF-accredited Detox/WM Residential.
  • Tarzana Treatment Centers (Tarzana, LA County) — multi-site listed tier with active DHCS licensure across LA Valley sites; ASAM 3.7 residential. CARF SUD accreditation status not verified in our most recent review.
  • American Recovery Center (Pomona, LA County) — multi-LOC, 123-bed residential, CARF across Detox/IOP/OP/Residential.

Malibu concierge AUD residential:

  • Passages (Malibu, LA County) — 6-bed, CARF Detox + Residential Treatment (BH). Luxury-tier; self-pay/OON billing typical.

Full directory at /facilities/, filterable by county, program type, and insurance acceptance.

Two clinical realities most AUD marketing obscures

First: MAT for alcohol is substantially underutilized. Despite strong evidence bases, naltrexone, acamprosate, and disulfiram are prescribed to a minority of AUD patients in residential and outpatient treatment. Some of this is patient preference (many patients decline medication in favor of peer-support-only recovery models), but much reflects provider-level familiarity gaps. If you or a family member has AUD and hasn’t been offered MAT, ask directly. MAT is not incompatible with 12-step or SMART Recovery or any behavioral modality; it’s an additional tool.

Second: the 28-day residential model is convention, not clinical evidence. The 28-day stay became dominant in the 1970s through insurance-coverage norms and has persisted despite ASAM Criteria’s clinical guidance supporting longer residential stays for moderate-to-severe AUD (60–90 days). Facilities offering only 28-day programs are operating within insurance-authorization norms, not necessarily within optimal clinical windows. For patients with severe AUD or prior treatment failures, asking about 60–90 day residential options is clinically reasonable.

AUD treatment outcomes — what the evidence base says

Long-term outcomes research for AUD treatment consistently supports three findings:

Medication improves outcomes: meta-analyses of naltrexone, acamprosate, and other pharmacotherapies demonstrate meaningful reductions in heavy drinking days and support for abstinence compared to placebo. Specific effect sizes vary across trials and patient populations; published meta-analyses have found statistically significant effects that are clinically meaningful for the treated population. Specific efficacy percentages vary by methodology and are less useful clinical anchors than the consistent finding that MAT-plus-behavioral-treatment outperforms behavioral-treatment-alone.

Integration of medication and behavioral treatment is optimal: patients receiving both FDA-approved medication and structured behavioral treatment (CBT, motivational enhancement, contingency management, 12-step facilitation, or other evidence-based modalities) have better outcomes than patients receiving either alone.

Duration matters: longer treatment engagement correlates with better outcomes. Short episodes of care (single-admission residential without continuing care) produce worse outcomes than continuous lower-intensity engagement across months to years.

Published outcome data for AUD maintenance shows meaningful reductions in heavy drinking days, increased abstinent days, and improved social and occupational functioning across multi-month follow-up windows. Specific response rates depend on patient population, concurrent behavioral treatment, comorbidities, and outcome measures. The clinically-honest framing: AUD is a chronic relapsing-remitting condition where sustained treatment produces sustained improvement, not a condition with a single “cure rate.”

AUD in specific populations

Alcohol-use disorder presents and responds to treatment differently across populations. Clinical considerations by population:

Women

  • Metabolism: women metabolize alcohol differently than men, reaching higher blood alcohol levels at lower doses. The clinical thresholds for “heavy drinking” and “risky drinking” are lower for women per NIAAA and AUDIT-guidance.
  • Liver injury: women develop alcoholic liver disease at lower cumulative exposures than men
  • Pregnancy: disulfiram is contraindicated in pregnancy; naltrexone’s safety profile in pregnancy is not fully established (US FDA pregnancy category C historically); acamprosate has more favorable reproductive data but still requires clinician judgment. For pregnant patients with AUD, specialized perinatal SUD programs coordinate high-risk OB/GYN and addiction medicine.
  • Fetal Alcohol Spectrum Disorders (FASD) prevention: any alcohol use in pregnancy carries FASD risk. Counseling and intensive support for pregnant patients is clinically essential.
  • Women-specific residential programs: Prototypes Women’s Center (Pomona, LA County, 164-bed flagship) and Alcoholism Center for Women (Los Angeles, 32-bed flagship) are SoCal women-specific residential options. Trauma-informed care is standard in women’s AUD programs given high prevalence of co-occurring trauma.

Older adults

  • Reduced alcohol tolerance with age; more toxic effects at lower doses
  • Polypharmacy concerns — AUD medications interact with medications commonly used in older adults (cardiovascular, psychiatric, pain management)
  • Falls risk: intoxication and withdrawal both increase fall risk, which has elevated morbidity in older adults
  • Cognitive screening — screen for alcohol-related cognitive impairment (Wernicke-Korsakoff, alcohol-related dementia) as part of assessment
  • Withdrawal severity: older adults often have more severe withdrawal from comparable drinking patterns
  • Program fit: older adults sometimes do poorly in younger-skewing residential cohorts; specialty older-adult SUD programming is limited but growing

Pregnant patients

  • Withdrawal in pregnancy: untreated alcohol withdrawal in pregnancy can cause fetal distress, miscarriage, and other adverse outcomes. Inpatient medical detox is typically indicated.
  • MAT in pregnancy: acamprosate has more favorable reproductive safety data than naltrexone or disulfiram. Specific clinical decision-making involves maternal-fetal medicine consultation.
  • Perinatal SUD programs: California has developed specialty perinatal SUD programs in most SoCal counties. LA County operates a Perinatal Services Network; OC, SD, Riverside, and other counties have similar programs.

LGBTQ+ populations

  • Elevated AUD prevalence: research consistently shows higher AUD rates in LGBTQ+ populations, particularly among transgender and bisexual populations
  • Minority stress theory: discrimination, rejection, and chronic stress are documented contributors
  • Treatment considerations: LGBTQ+-affirming programs reduce treatment-setting-related stress and improve engagement; non-affirming programs can deteriorate outcomes
  • SoCal LGBTQ+-specific or LGBTQ+-affirming programs: Los Angeles LGBT Center operates behavioral health services. Several CARF-accredited SoCal residential facilities hold LGBTQ+-affirming programming designations. Our LGBTQ+ facility specialty filter identifies these.

SoCal-specific alcohol mortality context

California’s published alcohol mortality data indicates tens of thousands of alcohol-related deaths annually statewide, including deaths from alcoholic liver disease, alcohol-related injury, and acute alcohol poisoning. Specific figures vary by reporting year and source methodology. The CDPH Chronic Disease Injury Control Branch publishes California-specific alcohol mortality reporting; LA County DPH publishes county-specific alcohol-attributable mortality on its health data portals.

Clinical context for the SoCal AUD treatment market: alcohol is the single most common primary substance in California DHCS-licensed residential admissions, across every insurance category and county. Of the 1,501 DHCS-active SUD facilities in SoCal, effectively all accept AUD patients as their primary or common presentation.

AUD treatment timeline — acute through maintenance

AUD treatment unfolds across predictable clinical phases with different care intensity at each.

Phase 1: Acute withdrawal (days 1–7): medical detox with CIWA-Ar-driven benzodiazepine protocol. ASAM 3.2-WM or 3.7-WM (or 4.0-WM for complicated cases). Primary clinical focus: preventing seizures, DTs, and medical complications; preparing patient for continuing care.

Phase 2: Post-acute withdrawal (days 8–14, sometimes longer): residual symptoms (sleep disturbance, mood instability, mild tremor, anxiety) can persist for 1–2 weeks. Residential treatment (ASAM 3.1, 3.3, 3.5, 3.7) or intensive outpatient (ASAM 2.5 PHP) is typical setting. MAT initiation often occurs here — naltrexone typically after 7–10 days of abstinence, acamprosate around day 5–7, disulfiram after full abstinence is stable.

Phase 3: Early recovery (weeks 2–12): step-down from residential to IOP or outpatient. Continuing behavioral treatment (CBT, motivational enhancement, contingency management). MAT continues. Peer-support engagement. Family therapy if clinically indicated.

Phase 4: Maintenance (months 3–12+): standard outpatient (ASAM 1.0), MAT continuation, peer-support maintenance. Duration variable but 6–12 months minimum engagement is clinically supported. Many patients maintain lower-intensity engagement indefinitely.

Phase 5: Long-term recovery (ongoing): episodic check-ins, MAT continuation as clinically indicated, peer-support maintenance. AUD is chronic; long-term low-intensity engagement produces better outcomes than treatment termination.

The transition from each phase to the next is clinically determined, not calendar-determined. Patients progressing well may step down earlier; patients with complications or relapse may need to step back up to higher-intensity care.

Peer-support modalities

Medical and clinical treatment for AUD pairs well with peer-support involvement. The major options:

  • Alcoholics Anonymous (AA) — 12-step abstinence-based model; largest peer-support network globally
  • SMART Recovery — cognitive-behavioral, science-informed, non-religious alternative
  • Refuge Recovery — Buddhist-informed recovery model
  • LifeRing Secular Recovery — non-religious peer support
  • Moderation Management — for patients whose goal is reduced drinking rather than abstinence (clinically appropriate for mild AUD, not severe)
  • Women for Sobriety, SOS (Secular Organizations for Sobriety) — specialized populations

Clinical guidelines support patient choice among evidence-based peer-support modalities. Mandating a specific modality is not clinically necessary; most facilities offer multiple options.

Insurance coverage for AUD treatment

Coverage specifics for AUD mirror other SUD coverage under federal MHPAEA and California SB 855 parity. See our dedicated pillars:

Need help with AUD treatment in Southern California?

Our editorial team can help you understand ASAM-level placement, MAT options, and which SoCal flagship facilities fit your clinical situation and insurance. We do not accept referral fees. Calls are informational.

Contact our editorial team →

Use the Verify Insurance tool →

Need help now? Call (310) 596-1751 for editorial guidance. If you or a family member is experiencing severe withdrawal symptoms — seizures, hallucinations, severe autonomic instability — call 911. Alcohol withdrawal can be fatal; do not attempt to detox at home with heavy chronic use or prior complications.

Last reviewed: 2026-04-23. ASAM Criteria references reflect the 4th edition. FDA-approved medication information reflects current labeling. This page is editorial content, not medical advice. For specific clinical decisions, consult a licensed addiction medicine physician.

Looking for treatment options in your area? We can help point you in the right direction. (310) 596-1751 — or request a callback.